Cleveland Clinic Abu Dhabi and Owkin launch AI platform for prostate cancer research and clinical support

Cleveland Clinic Abu Dhabi has launched a clinical AI platform developed with Owkin, named Aila, which the companies describe as the first of its kind. The platform is intended to support clinical decision-making and accelerate medical research using real patient data.

Aila is built on Owkin’s K Pro platform, described as an agentic system purpose-built for biology, and operates through a natural-language interface that allows physicians to query clinical datasets directly. The companies say the system is designed to reason across multiple data sources, generate insights and continue learning over time, reducing analysis that previously took days or weeks to a near-immediate response at the point of care.

Initial deployment will focus on prostate cancer, drawing on electronic health records, physician notes, pathology reports and medical imaging. Cleveland Clinic Abu Dhabi said the platform is intended to scale to additional specialties and incorporate further data types, including multi-omics and genomic data, to support precision medicine initiatives.

Dr Georges-Pascal Haber, chief executive of Cleveland Clinic Abu Dhabi, said the collaboration reflected the hospital’s commitment to innovation and that the platform was intended to support clinical judgement rather than replace it. He also linked the deployment to UAE government policy, describing the country’s regulatory environment as one that allows new health technologies to be tested in clinical settings.

Owkin has previously described its broader ambition in this area as building toward what it terms “Biological Artificial Superintelligence” in medicine. Aila is positioned as an early application of that approach within a hospital setting.